NASDAQ · OKYO
OKYO Pharma Limited
$1.48-$0.02 (-1.33%)
OKYO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 53.75% below the high.
Loading market information…
OTC · IGXT · USD
Stock price, earnings
Quote as of May 27, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
IntelGenx Technologies Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow IntelGenx Technologies Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
IntelGenx Technologies Corp. operates as a specialized drug delivery firm, concentrating on the creation and production of innovative oral thin film products for the pharmaceutical industry. Their current portfolio features several oral film formulations: INT0008/2008, a Rizatriptan product addressing migraine headaches; INT0046/2018, intended for adult applications; INT0007/2006, developed for the treatment of erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, aimed at combating opioid addiction; INT0010/2006, designed to alleviate neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film for schizophrenia or bipolar 1 disorder; and INT0048/2020, catering to animal health. Furthermore, IntelGenx is advancing additional projects in its development pipeline, specifically INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established various agreements, including licensing, development, and supply arrangements with Tilray, Inc., alongside a development partnership with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:15 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.48-$0.02 (-1.33%)
OKYO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 53.75% below the high.
$0.11-$0.01 (-9.69%)
Small Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.36% below the high.
$5.73$0.00 (0.0%)
Alpha Cognition Inc.: Healthcare · Biotechnology.
$0.03$0.00 (0.0%)
Pharmaxis Ltd: Healthcare · Drug Manufacturers - Specialty & Generic.
£0.03-£0.00 (-11.46%)
ImmuPharma PLC’s quoted price sits in the lower half of its reported 52-week range, 70.86% below the high.
$0.22$0.00 (0.0%)
Generation Hemp, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.7% below the high.
$1.00-$0.07 (-6.54%)
IBEX Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.09% below the high.
$2.74-$0.01 (-0.27%)
Organicell Regenerative Medicine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.86% below the high.
